REPORT OUTLOOK
Market Size | CAGR | Dominating Region |
---|---|---|
USD 8.27 billion | 15.8% | North America |
By Product | By Application | By Delivery |
---|---|---|
|
|
|
SCOPE OF THE REPORT
Biosimulation Market Overview
Biosimulation market size was valued at USD 2.21 billion in 2020 and is projected to reach USD 8.27 billion by 2029, growing at a CAGR of 15.8% from 2022 to 2029.
For drug research, biosimulation is becoming increasingly crucial. Biosimulation may be used to forecast if a potential drug will fail in the development process, such as clinical trials, due to undesirable side effects, poor pharmacokinetics, or even toxicity, given that only 11% of all drug candidates are approved. Early prediction of whether a medicine would fail in animals or people would be critical in reducing drug development expenses as well as the number of animal tests and clinical trials required. Biosimulation focuses on providing model-based predictions of biological system behaviour and dynamics. The huge increase in R&D spending by pharmaceutical and biotechnology businesses can be ascribed to the expansion of the worldwide biosimulation market. Furthermore, the expensive expense of re-running clinical trials as a result of the high failure rate in phase III clinical trials encourages the use of biosimulation in drug discovery and development, which promotes the market’s growth.
Breakthroughs in several parts of the medical industry have occurred at a rapid rate during the last several decades as a result of technological advancements and research activities. In recent years, the development of breakthrough treatments for a number of medical diseases and disorders has shifted gears, resulting in unprecedented demand for biosimulation– a factor that is projected to boost the biosimulation market’s growth during the assessment period. Biosimulation is utilised in drug discovery and development for a variety of purposes, including target identification and validation, lead optimization, and pre-clinical testing of new drugs.
ATTRIBUTE | DETAILS |
Study period | 2020-2029 |
Base year | 2021 |
Estimated year | 2022 |
Forecasted year | 2022-2029 |
Historical period | 2018-2020 |
Unit | Value (USD Billion) |
Segmentation | By Product, By Application, By Delivery, By End User and By Region |
By Product
 |
|
By Application
 |
|
By Delivery
 |
|
By End User
 |
|
By Region
 |
|
The recording, annotation, storage, analysis, and retrieval of nucleic acid sequence, protein sequence, and structural information are all covered by biosimulation. It has a variety of uses in health and biology, including molecular medications, preventive medicine, gene therapy, drug development, biotechnology, and microbial forensic investigation. It’s also employed in genetics and genomic research. The global biosimulation market is predicted to develop significantly in the near future, owing to an increase in demand for integrated data, a rise in demand for nucleic acid and protein sequencing due to lower sequencing costs, and an increase in proteomics and genomics applications. Moreover, drug research and development, as well as government and private-sector activities, are likely to drive market expansion over the projection period. The demand for integrated biosimulation systems in proteomics and genomics is also driving the biosimulation market forward.
A new drug’s development requires a significant quantity of research and resources. Every stage of the medication development process, from clinical trials through approval, has a significant risk of failure. Biosimulation can considerably lower these odds. Biosimulation not only aids in the prediction of medication failure throughout the development phase, but it also lowers the expense of any other potential failures by reducing the number of clinical trials required. Pharmaceutical companies (such as Pfizer, Merck, Novartis, and Johnson Pharmaceutical Research & Development) and research firms (such as Johnson Pharmaceutical Research & Development) have been using biosimulation software and service providers to reduce the length of trials and the high costs associated with failures.
Furthermore, the market’s growth is expected to be fueled by the clinical urgency to produce high-potency and sophisticated medications. Biosimulation is being more widely used in disease simulation modelling, such as diabetes mellitus. Models for advanced therapies are developed using it in conjunction with proteomic and genomic technology. As a result of ongoing technology developments and software upgrades, researchers’ interest in biosimulation is projected to expand. This is expected to provide the market a significant lift. Technical advancements include microarrays and prediction models, to name a few. Semantic systems that enable a restricted number of biosimulation elements have also been developed, decreasing the time, cost, and complexity of the entire process.
Biosimulation captures and processes various aspects of biological processes using a variety of models, tools, and languages. Current modelling methods fail to capture the fundamental semantics of biosimulation models, making it difficult to construct, reuse, compose, and merge diverse, complicated biosimulation models. The use of in silico or biosimulation technology in the drug research or development process has yet to be standardised by regulatory agencies. Biomedical researchers’ computing power for constructing and operating sophisticated biosimulation systems has increased as a result of recent technology developments. Researchers, on the other hand, are finding it more difficult to communicate, manage, and change their models as their models and simulations become more complicated. The lack of scalable standards for model representation and reuse exacerbates the challenge of sharing sophisticated biomedical models. As a result, many model developers are unable to exchange and construct new models based on existing models. This weakness of biosimulation can only be addressed by developing a systematic, standards-based representation model that can unambiguously express biosimulation data in both human and machine-readable formats. As a result, the biosimulation community is in desperate need of tools to help them construct, manage, and reuse their models more efficiently.
Biosimulation Market Segment Analysis
The market is broadly segmented into product, application, delivery, end user and region. Based on product & service, the biosimulation market is segmented into software and services. The biosimulation software segment is expected to account for the largest market share. The increasing usage of biosimulation software by pharmaceutical and research firms, as well as increased R&D investment for pharmaceutical research, are driving this segment’s rapid rise.
Based on end user, research institutes, pharmaceutical and biotechnology businesses, contract research organisations (CROs), regulatory authorities, and other end users make up the biosimulation market (consulting firms, defence research and development organizations, nutraceutical companies, and food and agricultural companies). Pharmaceutical and biotechnology firms are likely to account for the greatest share, with the highest CAGR throughout the forecast period. Increased pharmaceutical and biotechnology R&D spending, as well as increased adoption of inorganic development strategies by various biosimulation service providers, are expected to drive biosimulation solutions adoption in the pharmaceutical and biotechnology industries.
Biosimulation Market Players
Certara, Simulations Plus Inc, Dassault Systèmes, Schrödinger, ACD/Labs, Chemical Computing Group, Physiomics, Evidera, InSilico Biosciences, INOSIM Software, Insilico Biotechnology, LeadInvent Technologies, Rosa, Nuventra Pharma, and Genedata are some of the major players in the market that are dominating the market.
- Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
- Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity modelling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries.
- Dassault Systèmes SE is a French software corporation, which develops software for 3D product design, simulation, manufacturing and other 3D related products.
Who Should Buy? Or Key Stakeholders
- Software Industry
- Pharmaceutical Industry
- Healthcare Industry
- Biotechnology Companies
- Hospitals and Clinics
- Scientific Research and Development
- Investors
- Manufacturing companies
- End user companies
Biosimulation Market Regional Analysis
The global biosimulation market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
- Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
- South America: includes Brazil, Argentina and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
With a market share of 44 percent in 2021, North America dominated the biosimulation market. Growth in the biotechnology and pharmaceutical industries, a significant number of active drug development processes, growing usage of personalised medicine, and higher R&D expenditure by pharmaceutical and biotechnology businesses are all contributing to the North American market’s dominance.
Key Market Segments: Biosimulation Market
Biosimulation Market by Product, 2020-2029, (USD Million)
- Software
- Molecular Simulation
- In House
- Contract Services
Biosimulation Market by Application, 2020-2029, (USD MILLION)
- Clinical Trials
- PKPD
- ADME
Biosimulation Market by Delivery, 2020-2029, (USD Million)
- Subscription
- Ownership
Biosimulation Market by End User, 2020-2029, (USD MILLION)
- BIOTECH
- PHARMA COMPANIES
- CROS
- REGULATORY
Biosimulation Market By Region, 2020-2029, (USD MILLION)
- North America
- Europe
- Asia Pacific
- South America
- Middle East And Africa
Important Countries In All Regions Are Covered.
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL BIOSIMULATION MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON GLOBAL BIOSIMULATION MARKET
- GLOBAL BIOSIMULATION MARKET OUTLOOK
- GLOBAL BIOSIMULATION MARKET BY PRODUCT, (USD MILLION)
- SOFTWARE
- MOLECULAR SIMULATION
- IN HOUSE
- CONTRACT SERVICES
- GLOBAL BIOSIMULATION MARKET BY DELIVERY, (USD MILLION)
- SUBSCRIPTION
- OWNERSHIP
- GLOBAL BIOSIMULATION MARKET BY APPLICATION, (USD MILLION)
- CLINICAL TRIALS
- PKPD
- ADME
- GLOBAL BIOSIMULATION MARKET BY END USER, (USD MILLION)
- BIOTECH
- PHARMA COMPANIES
- CROS
- REGULATORY
- GLOBAL BIOSIMULATION MARKET BY REGION, (USD MILLION)
- INTRODUCTION
- ASIA-PACIFIC
- CHINA
- INDIA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA-PACIFIC
- NORTH AMERICA
- UNITED STATES
- CANADA
- MEXICO
- EUROPE
- GERMANY
- UNITED KINGDOM
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- COMPANY PROFILES*(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)
-
- CERTARA
- SIMULATIONS PLUS INC
- DASSAULT SYSTÈMES
- SCHRÖDINGER
- ACD/LABS
- CHEMICAL COMPUTING GROUP
- PHYSIOMICS
- EVIDERA
- INSILICO BIOSCIENCES
- INOSIM SOFTWARE
- INSILICO BIOTECHNOLOGY
- OTHERS *THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â Â Â GLOBAL BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS)2020-2029
TABLE 2Â Â Â Â Â Â Â Â Â GLOBAL BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 3Â Â Â Â Â Â Â Â Â GLOBAL BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 4Â Â Â Â Â Â Â Â Â GLOBAL BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 5Â Â Â Â Â Â Â Â Â GLOBAL BIOSIMULATION MARKET BY REGION (USD MILLIONS) 2020-2029
TABLE 6Â Â Â Â Â Â Â Â Â US BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 7Â Â Â Â Â Â Â Â Â US BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 8Â Â Â Â Â Â Â Â US BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 9Â Â Â Â Â Â Â Â US BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 10Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 11Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 12Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 13Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 14Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 15Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 16Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 17Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 18Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 19Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 20Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 21Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 22Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 23Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 24Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 25Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 26Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 27Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 28Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 29Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 30Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 31Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 32Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 33Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 34Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 35Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 36Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 37Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 38Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 39Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 40Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 41Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 42Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 43Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 44Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 45Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 46Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 47Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 48Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 49Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 50Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 51Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 52Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 53Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 54Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 55Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 56Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 57Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 58Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 59Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 60Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 61Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 62Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 63Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 64Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 65Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 66Â Â Â Â Â Â Â Â Â Â Â Â Â UK BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 67Â Â Â Â Â Â Â Â Â Â Â Â Â UK BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 68Â Â Â Â Â Â Â Â Â Â Â Â Â UK BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 69Â Â Â Â Â Â Â Â Â Â Â Â Â UK BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 70Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 71Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 72Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 73Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 74Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 75Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 76Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 77Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 78Â Â Â Â Â Â Â Â Â Â Â Â Â SPAIN BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 79Â Â Â Â Â Â Â Â Â Â Â Â Â SPAIN BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 80Â Â Â Â Â Â Â Â Â Â Â Â Â SPAIN BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 81Â Â Â Â Â Â Â Â Â Â Â Â Â SPAIN BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 82Â Â Â Â Â Â Â Â Â Â Â Â Â RUSSIA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 83Â Â Â Â Â Â Â Â Â Â Â Â Â RUSSIA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 84Â Â Â Â Â Â Â Â Â Â Â Â Â RUSSIA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 85Â Â Â Â Â Â Â Â Â Â Â Â Â RUSSIA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 86Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 87Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 88Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 89Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 90Â Â Â Â Â Â Â Â Â Â Â Â Â UAE BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 91Â Â Â Â Â Â Â Â Â Â Â Â Â UAE BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 92Â Â Â Â Â Â Â Â Â Â Â Â Â UAE BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 93Â Â Â Â Â Â Â Â Â Â Â Â Â UAE BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 94Â Â Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 95Â Â Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 96Â Â Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 97Â Â Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 98Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 99Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 100Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 101Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
TABLE 102Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA BIOSIMULATION MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 103Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA BIOSIMULATION MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 104Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA BIOSIMULATION MARKET BY END USER (USD MILLIONS) 2020-2029
TABLE 105Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA BIOSIMULATION MARKET BY DELIVERY (USD MILLIONS) 2020-2029
LIST OF FIGURES
FIGURE 1Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â GLOBAL BIOSIMULATION MARKET BY PRODUCT, USD MILLION, 2020-2029
FIGURE 10Â Â Â GLOBAL BIOSIMULATION MARKET BY DELIVERY, USD MILLION, 2020-2029
FIGURE 11Â Â Â GLOBAL BIOSIMULATION MARKET BY APPLICATION, USD MILLION, 2020-2029
FIGURE 12Â Â Â GLOBAL BIOSIMULATION MARKET BY END USER, USD MILLION, 2020-2029
FIGURE 13Â Â Â GLOBAL BIOSIMULATION MARKETBY REGION, USD MILLION, 2020-2029
FIGURE 14   PORTER’S FIVE FORCES MODEL
FIGURE 15Â Â Â GLOBAL BIOSIMULATION MARKETBY PRODUCT, 2020
FIGURE 16Â Â Â GLOBAL BIOSIMULATION MARKETBY DELIVERY 2020
FIGURE 17Â Â Â GLOBAL BIOSIMULATION MARKETBY APPLICATION 2020
FIGURE 18Â Â Â GLOBAL BIOSIMULATION MARKET BY END USER 2020
FIGURE 19Â Â Â BIOSIMULATION MARKETBY REGION 2020
FIGURE 20Â Â Â MARKET SHARE ANALYSIS
FIGURE 21Â Â Â CERTARA: COMPANY SNAPSHOT
FIGURE 22Â Â Â SIMULATIONS PLUS INC: COMPANY SNAPSHOT
FIGURE 23   DASSAULT SYSTÈMES: COMPANY SNAPSHOT
FIGURE 24   SCHRÖDINGER: COMPANY SNAPSHOT
FIGURE 25Â Â Â ACD/LABS: COMPANY SNAPSHOT
FIGURE 26Â Â Â CHEMICAL COMPUTING GROUP: COMPANY SNAPSHOT
FIGURE 27Â Â Â PHYSIOMICS: COMPANY SNAPSHOT
FIGURE 28Â Â Â EVIDERA: COMPANY SNAPSHOT
FIGURE 29Â Â Â INSILICO BIOSCIENCES: COMPANY SNAPSHOT
FIGURE 30Â Â Â INOSIM SOFTWARE: COMPANY SNAPSHOT
FAQ
Biosimulation market size was valued at USD 2.21 billion in 2020 and is projected to reach USD 8.27 billion by 2029, growing at a CAGR of 15.8% from 2022 to 2029.
North America held more than 44% of the Biosimulation market revenue share in 2021 and will witness expansion in the forecast period.
In recent years, the development of breakthrough treatments for a number of medical diseases and disorders has shifted gears, resulting in unprecedented demand for biosimulation– a factor that is projected to boost the biosimulation market’s growth during the assessment period. Biosimulation is utilised in drug discovery and development for a variety of purposes, including target identification and validation, lead optimization, and pre-clinical testing of new drugs.
The leading application of Biosimulation market in 2020 was pharmaceutical market segment. It has the biggest market share.
North America held the largest market share of Biosimulation market.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.